Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 plus gemcitabine/cisplatin in potentially resectable biliary tract malignancies (Phase II, single arm)
ChiCTR2400085953Phase 2Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- May 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in biliary cancer, sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Surgical conversion success rate. Started May 2024; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2400085953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085953.